---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-033256"
form_type: "8-K"
ticker: null
cik: "0000922247"
company_name: "Cyclo Therapeutics, Inc."
filed_at: "2023-11-30T23:59:59+00:00"
generated_at: "2026-06-07T20:10:25.123495+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cyclo Therapeutics receives Nasdaq delisting notice for low equity; expects cure via AMTI merger

## Summary
- Stockholders' equity of $1,052,670 as of Sep 30, 2023, below Nasdaq's $2.5M minimum.
- Nasdaq scheduled trading suspension for Dec 6, 2023 unless appeal; company will request hearing by Dec 4.
- Company expects to meet equity requirement by year-end using cash from pending merger with Applied Molecular Transport (AMTI).
- Merger agreement signed Sep 21, 2023; S-4 declared effective Nov 21, proxy mailed Nov 27.

## SEC filing metadata
- accession: 0001437749-23-033256
- form_type: 8-K
- cik: 0000922247
- company_name: Cyclo Therapeutics, Inc.
- filed_at: 2023-11-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/922247/000143774923033256/0001437749-23-033256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/922247/000143774923033256/ctdh20231129_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-033256
- JSON: https://secwatch.observer/filing/0001437749-23-033256.json
- Plain text: https://secwatch.observer/filing/0001437749-23-033256.txt

## Key facts
- Listing & Compliance Notices
  Cyclo Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)
  source text: November 27, 2023, Cyclo Therapeutics, Inc. (the “ Company ” ) received written notice (“ Notice ”) from the Nasdaq Stock Market (“ Nasdaq ”) stating that the Company does not comply with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b) for continued listing on The Nasdaq Capital Market because the Company’s stockholders’ equity, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, is below $2.5 million (i.e., $1,052,670). In addition, the Company does not meet the alternative compliance standards relating t
  evidence_url: https://www.sec.gov/Archives/edgar/data/922247/000143774923033256/0001437749-23-033256-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.